6.43%QQQQ 31.68 5.74%INTC 15.57 2.26%
Digg
Del.icio.us
Newsvine 
Facebook
Stumbleupon
NEW YORK - Shares of biotechnology companies are trading lower Friday, after Genentech reported lower-than-expected quarterly revenue due to disappointing sales of cancer drug Avastin. Thomas Weisel Partners analyst M. Ian Somaiya downgraded the stock to "Market Weight" from "Overweight," forecasting "tepid growth" until 2009.
Here's how shares of some biotech firms performed shortly after the market's open:
San Francisco-based Genentech Inc. slipped 55 cents to $77.45
Cambridge, Mass.-based Biogen Idec Inc fell $1.43, or 2.2 percent, to $65
Foster City, Calif.-based Gilead Sciences Inc., which has held strong in its sector due to growth in its HIV franchise, saw shares dip $1.08, or 2.1 percent, to $51.01
Thousand Oaks, Calif.-based Amgen Inc. fell 41 cents to $43.57
The sole member of the Amex Biotechnology Index bucking the downward trend was PDL BioPharma Inc., after the Redwood City, Calif.-based company said late Thursday it will spinoff its biotechnology assets into a separate company and pay shareholders a special $4.25 dividend.
Shares spiked $1.82, or 15.5 percent, to $13.53.
Investor Julian Roberts believes the poor economy could last as long as 10 to 15 years, according to CNBC.
Joey Chestnut set a new fast-eating record when he ate 45 pizza slices in 10 min...
Oil prices rebounded from a 13-month low to rise above $81 a barrel Monday in As...
Get your next web design project done with our los angeles web design team - Best web design with great price.
|
Partners   
|
© 2008 The Ibtimes Company. All Rights Reserved. Terms of service | Privacy Policy | Advertising | About Us | Contact Us | Archives
EMAIL
PRINT
RSS
SHARE
3.02
-1.48
